CDH2 and urinary bladder cancer: In our study, SCAMP2 overexpression was found to promote the EMT process, evidenced by the downregulation of the epithelial marker CDH1 and the upregulation of the mesenchymal marker CDH2, thereby enhancing cisplatin resistance in bladder cancer.